- Home
- SLRN vs CRDF Comparison
SLRN vs CRDF Comparison
Compare SLRN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRN
- CRDF
- Stock Information
- Founded
- SLRN 2020
- CRDF 1999
- Country
- SLRN United States
- CRDF United States
- Employees
- SLRN N/A
- CRDF N/A
- Industry
- SLRN Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRN Health Care
- CRDF Health Care
- Exchange
- SLRN Nasdaq
- CRDF Nasdaq
- Market Cap
- SLRN 224.6M
- CRDF 185.6M
- IPO Year
- SLRN 2023
- CRDF N/A
- Fundamental
- Price
- SLRN $2.34
- CRDF $3.05
- Analyst Decision
- SLRN Hold
- CRDF Strong Buy
- Analyst Count
- SLRN 5
- CRDF 4
- Target Price
- SLRN $9.60
- CRDF $12.00
- AVG Volume (30 Days)
- SLRN 970.9K
- CRDF 1.5M
- Earning Date
- SLRN 05-12-2025
- CRDF 05-05-2025
- Dividend Yield
- SLRN N/A
- CRDF N/A
- EPS Growth
- SLRN N/A
- CRDF N/A
- EPS
- SLRN N/A
- CRDF N/A
- Revenue
- SLRN N/A
- CRDF $683,000.00
- Revenue This Year
- SLRN $267.11
- CRDF N/A
- Revenue Next Year
- SLRN N/A
- CRDF N/A
- P/E Ratio
- SLRN N/A
- CRDF N/A
- Revenue Growth
- SLRN N/A
- CRDF 39.96
- 52 Week Low
- SLRN $1.85
- CRDF $2.01
- 52 Week High
- SLRN $7.25
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- SLRN 47.95
- CRDF 48.11
- Support Level
- SLRN $2.17
- CRDF $2.73
- Resistance Level
- SLRN $2.32
- CRDF $3.04
- Average True Range (ATR)
- SLRN 0.18
- CRDF 0.24
- MACD
- SLRN -0.00
- CRDF 0.06
- Stochastic Oscillator
- SLRN 33.88
- CRDF 95.83
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.